key: cord-0967169-d6g0ppfu authors: Tsuchida, Tomoya; Nitahara, Yuko; Suzuki, Shotaro; Komase, Yuko; Candray, Katherine; Kido, Yasutoshi; Nakagama, Yu; Yamasaki, Yukitaka; Imamura, Mitsuru; Kawahata, Kimito; Kunishima, Hiroyuki; Fujitani, Shigeki; Mineshita, Masamichi; Matsuda, Takahide title: Back to normal; serological testing for COVID‐19 diagnosis unveils missed infections date: 2021-03-25 journal: J Med Virol DOI: 10.1002/jmv.26949 sha: ee67e02e2b4bcf2b3155a0966f5b938131781291 doc_id: 967169 cord_uid: d6g0ppfu BACKGROUND: The gold standard for coronavirus disease (COVID‐19) diagnosis has been the detection of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) RNA by nucleic acid amplification testing (NAAT). On the other hand, serological testing for COVID‐19 may offer advantages in detecting possibly overlooked infections by NAAT. METHODS: To evaluate seroconversion of NAAT‐negative pneumonia patients, immunoglobulin M (IgM) and IgG targeting the spike protein of SARS‐CoV‐2 were semiquantified by an immunofluorescence assay. Seroconversion was confirmed by another serological method, targeting the nucleocapsid protein. RESULTS: Eight suspected but unconfirmed COVID‐19 pneumonia patients (median age, 39 years; range, 21–55) were included. The median period between symptom onset and NAAT sample collection was 6 days (2–27 days). None of them had tested positive for SARS‐CoV‐2 by NAAT. In contrast, all eight patients revealed seropositivity with the two serological methods, indicating actual seroconversion against SARS‐CoV‐2. The median period between onset and blood sampling was 26.5 days (7–51 days). CONCLUSION: Eight patients with COVID‐19 pneumonia, initially tested negative for SARS‐CoV‐2 by NAAT, were finally confirmed of the diagnosis by serological testing. To cover the whole spectrum of this heterogenous infectious disease, serology testing should be implemented to the multitiered diagnostic algorithm for COVID‐19. Human history is often described as man's endless battle against infectious diseases. None of these battles would have ever settled without the development of reliable diagnostic measures. Two distinct approaches exist in the diagnosis of an infectious disease. One approach aims to catch the pathogen by a nucleic acid or antigen detection in materials derived from biological specimens. On the other hand, serological testing analyzes the host immune response against the pathogen. Both approaches harbor unique pros and cons, and thus are often used in combination to form a multitiered diagnostic algorithm. The fundamental structure of this multitiered diagnostic approach shall be strictly followed even when we encounter a novel pathogen, as in the current pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the outbreak at the end of 2019, the gold standard for coronavirus disease (COVID-19) diagnosis has been the detection of the unique RNA sequences of the virus by nucleic acid amplification testing (NAAT). 1 However, NAAT has substantial limitations. Study groups have reported that the viral load of SARS-CoV-2 in the upper respiratory tracts peaks out within days from symptom onset, and the window of viral detection by NAAT may be limited up to 20 days from disease onset. 2 In contrast, the rise in antibody titer observed as early as 5 days from disease onset may last up to 4 months. 3, 4 Considering these reports, serological testing for COVID-19 may offer advantages in detecting low viral load infections and in extending the window period for disease recognition as well. 5 Combining both approaches shall potentially cover the whole spectrum of the heterogenous SARS-CoV-2 infection and offer a suitable diagnostic algorithm. Herein, we report a case series of eight patients with pneumonia who, although had initially tested negative for NAAT, were finally confirmed of COVID-19 by serological testing. All patients provided written consent to participate in this study. This study was approved by the institutional review board (#2020-003). Information Table) , indicating actual seroconversion against SARS-CoV-2. Although these cases remained negative for NAAT, we considered, with the two positive results from independent SARS-CoV-2-specific antibody assays, that positive predictivity is sufficiently high to declare them as "serologically confirmed COVID-19" cases. 6 Serological analyses for SARS-CoV-2 have been predominantly applied for epidemiological and surveillance purposes. 6, 7 The discussion over whether applying serological testing for individual patient care shall be beneficial has not reached a clear consensus. 1, 8 Considering the limited diagnostic performance of NAAT, however, serological testing should be readily considered, not exactly as an alternative but as the indispensable counterpart of the COVID-19 diagnostic algorithm. 9, 10 As the growing literature describes the nature of COVID-19, we are coming to realize the difficulty in defining the truly affected population. This is mainly due to disease heterogeneity, that is, the variety in clinical manifestations and, as well, the unique tropism of SARS-CoV-2. 2-6 Indeed, false-negative results can lead to overlooking the diagnosis and cause serious consequences, especially in vulnerable communities (e.g., health facilities). 10 To combat this situation, it is necessary to grasp the overall spectrum of the disease by implementing all different tiers of the fundamental diagnostic approaches. Following the diagnostic norms, combining NAAT and serological testing shall maximize disease recognition and is therefore essential in finding our way back to normal. Centers for Disease Control and Prevention. Overview of testing for SARS-CoV-2 (COVID-19 COVID-19-lessons learned and questions remaining Profiling early humoral response to diagnose novel coronavirus disease (COVID-19) Humoral immune response to SARS-CoV-2 in Iceland Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure Prevalence of SARS-CoV-2-specific antibodies The power of antibody-based surveillance Seroconversion against SARS-CoV-2 occurred after the recovery in patients with COVID-19 SARS-CoV-2 serological testing changes disease management in a PCR-negative patient False negative tests for SARS-CoV-2 infection-challenges and implications The data that supports the findings of this study are available in the supplementary material of this article.